Skip to main content

Table 4 Subgroup analysis according to disease severity and hospital outcomes between COVID-19 patients treated with and without inhaled ciclesonide

From: Clinical benefits of inhaled ciclesonide for hospitalized patients with COVID-19 infection: a retrospective study

 

Severe COVID-19 infection

Not severe COVID-19 infection

 

Ciclesonide (n = 118)

No ciclesonide (n = 34)

p value

Ciclesonide (n = 66)

No ciclesonide (n = 51)

p value

Initiated supplemental oxygen after admission

Not applicable

38 (57.6%)

17 (33.3%)

0.0095

Mechanical ventilation

18 (15.3%)

11 (32.4%)

0.0259

5 (7.6%)

1 (2.0%)

0.2301

In-hospital mortality

8 (6.8%)

17 (50.0%)

< 0.0001

6 (9.1%)

3 (5.9%)

0.7296

 

High Shang’s CSS risk

Low Shang’s CSS risk

 

Ciclesonide (n = 61)

No ciclesonide (n = 37)

p value

Ciclesonide (n = 118)

No ciclesonide (n = 41)

p value

Initiated supplemental oxygen after admission

9 (14.8%)

8(21.6%)

0.3865

27 (22.9%)

9 (22.0%)

0.9027

Mechanical ventilation

9 (14.8%)

8 (21.6%)

0.3865

14 (11.9%)

4 (9.8%)

> 0.9999

In-hospital mortality

10 (16.4%)

16 (43.2%)

0.0037

2 (1.7%)

2 (4.9%)

0.2738

  1. COVID-19 coronavirus disease 2019; Shang’s CSS Shang’s COVID-19 scoring system